Literature DB >> 20494739

Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Jeff Reese1, Alex Veldman, Lisa Shah, Megan Vucovich, Robert B Cotton.   

Abstract

Premature birth and disruption of the normal maturation process leave the immature ductus arteriosus unable to respond to postnatal cues for closure. Strategies that advocate conservative management of the patent ductus arteriosus (PDA) in premature infants are dependent on identification of the symptomatic PDA and understanding the risk factors that predispose to PDA. Exposure of premature infants to unintended vasodilatory stimuli may be one of the risk factors for PDA that is under recognized. In this article, we summarize the clinical factors that are associated with PDA and review commonly used neonatal drugs for their vasodilatory properties. Data demonstrating relaxation of the ductus arteriosus by gentamicin and other aminoglycoside antibiotics, by cimetidine and other H2 receptor antagonists, and by heparin are provided as examples of neonatal therapies that have unanticipated effects that may promote PDA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494739      PMCID: PMC2920501          DOI: 10.1053/j.semperi.2010.02.007

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  90 in total

1.  Incidence and risk factors associated with the patency of ductus arteriosus in preterm infants with respiratory distress syndrome in Kuwait.

Authors:  Majeda S Hammoud; Hassan A Elsori; Emad-Aldeen M Hanafi; Adel A Shalabi; Ibrahim A Fouda; Lakshmi V Devarajan
Journal:  Saudi Med J       Date:  2003-09       Impact factor: 1.484

2.  Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.

Authors:  Roberta L Keller; Theresa A Tacy; Scott Fields; John P Ofenstein; Jacob V Aranda; Ronald I Clyman
Journal:  Pediatr Res       Date:  2005-12       Impact factor: 3.756

3.  Patent ductus arteriosus in a cohort of 1338 preterm infants: a collaborative study.

Authors:  M van de Bor; S P Verloove-Vanhorick; R Brand; J H Ruys
Journal:  Paediatr Perinat Epidemiol       Date:  1988-10       Impact factor: 3.980

4.  Perinatal risk assessment for patent ductus arteriosus in premature infants.

Authors:  M D Cunningham; R C Ellison; S Zierler; W P Kanto; O S Miettinen; A S Nadas
Journal:  Obstet Gynecol       Date:  1986-07       Impact factor: 7.661

Review 5.  Umbilical artery catheters in the newborn: effects of heparin.

Authors:  K J Barrington
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

7.  Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.

Authors:  M A Rojas; A Gonzalez; E Bancalari; N Claure; C Poole; G Silva-Neto
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

8.  The hemodynamic effects of heparin and their relation to ionized calcium levels.

Authors:  P Urban; D Scheidegger; B Buchmann; K Skarvan
Journal:  J Thorac Cardiovasc Surg       Date:  1986-02       Impact factor: 5.209

9.  Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex.

Authors:  M Levine; G D Bellward
Journal:  Drug Metab Dispos       Date:  1995-12       Impact factor: 3.922

10.  Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates.

Authors:  Andras Treszl; Miklos Szabo; Gyorgy Dunai; Andras Nobilis; Istvan Kocsis; Tamas Machay; Tivadar Tulassay; Barna Vasarhelyi
Journal:  Pediatr Res       Date:  2003-08-06       Impact factor: 3.756

View more
  13 in total

1.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

Review 2.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

3.  Antenatal calcium channel blocker exposure and subsequent patent ductus arteriosus in extremely low-birth-weight infants.

Authors:  Jennifer McGuirl; Bonnie Arzuaga; Ben H Lee
Journal:  Pediatr Cardiol       Date:  2011-08-23       Impact factor: 1.655

4.  Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.

Authors:  J E Constance; D Reith; R M Ward; A Balch; C Stockmann; E K Korgenski; E A Thorell; C M T Sherwin
Journal:  J Perinatol       Date:  2017-06-08       Impact factor: 2.521

5.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

6.  Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.

Authors:  Megan M Vucovich; Robert B Cotton; Elaine L Shelton; Jeremy A Goettel; Noah J Ehinger; Stanley D Poole; Naoko Brown; James L Wynn; Bibhash C Paria; James C Slaughter; Reese H Clark; Mario A Rojas; Jeff Reese
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-03       Impact factor: 4.733

7.  Pharmacogenetics in clinical pediatrics: challenges and strategies.

Authors:  Sara L Van Driest; Tracy L McGregor
Journal:  Per Med       Date:  2013-09       Impact factor: 2.512

8.  Congenital Heart Disease Requiring Maintenance of Ductus Arteriosus in Critically Ill Newborns Admitted at a Tertiary Neonatal Intensive Care Unit.

Authors:  Manuela Cucerea; Marta Simon; Elena Moldovan; Marcela Ungureanu; Raluca Marian; Laura Suciu
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-11-08

9.  Association of chorioamnionitis and patent ductus arteriosus in a national U.S. cohort.

Authors:  Celeste A Green; Daniel Westreich; Matthew M Laughon; David M Stamilio; Robert A Strauss; Jeff Reese; Elaine L Shelton; Kartik K Venkatesh
Journal:  J Perinatol       Date:  2020-10-22       Impact factor: 2.521

Review 10.  Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions.

Authors:  Smita Akkinapally; Shilpa G Hundalani; Madhulika Kulkarni; Caraciolo J Fernandes; Antonio G Cabrera; Binoy Shivanna; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2018-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.